| 5.22 -0.17 (-3.15%) | 08-13 14:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.33 |
1-year : | 6.85 |
| Resists | First : | 5.42 |
Second : | 5.86 |
| Pivot price | 5.1 |
|||
| Supports | First : | 4.71 |
Second : | 3.91 |
| MAs | MA(5) : | 5.11  |
MA(20) : | 5.2 |
| MA(100) : | 6.65 |
MA(250) : | 5.97 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 40.4 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 8.73 | Low : | 3.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ UNCY ] has closed below upper band by 48.3%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.54 - 5.57 | 5.57 - 5.6 |
| Low: | 4.97 - 5 | 5 - 5.04 |
| Close: | 5.33 - 5.39 | 5.39 - 5.44 |
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Thu, 13 Aug 2026
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Wed, 12 Aug 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - IndyStar
Wed, 12 Aug 2026
Unicycive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Wed, 12 Aug 2026
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - tradingview.com
Wed, 12 Aug 2026
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Wed, 12 Aug 2026
Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 41.4 (%) |
| Shares Short | 4,940 (K) |
| Shares Short P.Month | 3,240 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -163.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.28 |
| PEG Ratio | 0 |
| Price to Book value | 3.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|